BeyondSpring Inc. (BYSI): Total Liabilities
$49.92M
As of 2025-12-31
$50.63M
As of 2026-06-30
+0.5%
3-year compound annual growth
+14.6%
5-year compound annual growth
+43.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $49.92M | +2.7% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $48.60M | +0.7% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $48.27M | -2.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $49.23M | -10.9% | 2023-04-18, Balance as of period end |
| 2021-12-31 | $55.27M | +119.2% | 2023-04-18, Balance as of period end |
| 2020-12-31 | $25.22M | +87.9% | 2022-04-14, Balance as of period end |
| 2019-12-31 | $13.42M | -18.4% | 2021-04-30, Balance as of period end |
| 2018-12-31 | $16.45M | +243.2% | 2020-04-30, Balance as of period end |
| 2017-12-31 | $4.79M | +83.7% | 2019-04-30, Balance as of period end |
| 2016-12-31 | $2.61M | +98.9% | 2018-04-03, Balance as of period end |
| 2015-12-31 | $1.31M | n/a | 2017-04-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $49.92M | +2.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare BYSI, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗